公开(公告)号：US20230310388A1

公开(公告)日：2023-10-05

申请号：US17996655

申请日：2021-04-23

申请人： Neoculi Pty Ltd

发明人： Stephen Page ,  Adam McCluskey ,  Martine Keenan ,  Andrew Stevens ,  Sanjay Garg

IPC分类号： A61K31/433 ,  A61K31/498 ,  A61K31/428 ,  A61K31/4709 ,  A61K31/4164 ,  A61K31/245 ,  A61P31/10

CPC分类号： A61K31/433 ,  A61K31/498 ,  A61K31/428 ,  A61K31/4709 ,  A61K31/4164 ,  A61K31/245 ,  A61P31/10

摘要： Provided herein are methods of treating or preventing a fungal colonisation or infection in a subject. The method includes administering a therapeutically effective amount of a compound, or a therapeutically acceptable salt thereof, to the subject, wherein the fungal colonisation or infection is caused by a fungal agent. In certain embodiments, the compound is a compound of Formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof:

公开(公告)号：US20230301984A1

公开(公告)日：2023-09-28

申请号：US18014045

申请日：2021-07-01

申请人： The USA, as represented by the Secretary, Department of Health and Human Services

发明人： Anand Swaroop ,  Yu Holly Chen ,  Manju Swaroop ,  Wei Zheng ,  Gregory Tawa ,  Anupam Mondal ,  Samantha Papal ,  Wenwei Huang ,  Zhiji Luo

IPC分类号： A61K31/475 ,  A61K31/473 ,  A61P27/02 ,  A61K31/498

CPC分类号： A61K31/475 ,  A61K31/473 ,  A61K31/498 ,  A61P27/02

摘要： Method embodiments are disclosed for treating retinal degeneration in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of compound, and/or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, or tautomer thereof, selected from 3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol hydrochloride or a compound having a structure according to a formula selected from Formula I, II, or III, as described herein. In some non-limiting examples, the subject has retinitis pigmentosa, LCA, Stargardt’s macular dystrophy, cone-rod dystrophy, choroideremia or age-related macular degeneration.

公开(公告)号：US11730724B2

公开(公告)日：2023-08-22

申请号：US17082902

申请日：2020-10-28

申请人： Bow River LLC

发明人： Sundar Srinivasan ,  Christina Chow

IPC分类号： A61K31/4468 ,  A61K31/454 ,  A61K31/519 ,  A61K31/498 ,  A61K31/497 ,  A61K31/506 ,  A61K31/407 ,  A61P35/04 ,  A61K9/00 ,  A61K31/5383 ,  A61P25/18 ,  A61K31/4995 ,  A61P25/16 ,  A61K31/4745 ,  A61K31/397 ,  A61K31/5395 ,  A61P35/02 ,  A61K9/08 ,  A61K9/20 ,  A61K9/48 ,  A61K31/00 ,  A61K9/10

CPC分类号： A61K31/4468 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/0078 ,  A61K9/0095 ,  A61K9/08 ,  A61K9/10 ,  A61K9/2004 ,  A61K9/4841 ,  A61K31/00 ,  A61K31/397 ,  A61K31/407 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/498 ,  A61K31/4995 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5383 ,  A61K31/5395 ,  A61P25/16 ,  A61P25/18 ,  A61P35/02 ,  A61P35/04

摘要： The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

公开(公告)号：US20230226040A1

公开(公告)日：2023-07-20

申请号：US17991482

申请日：2022-11-21

申请人： Incyte Corporation

发明人： Alejandro Amador Arjona ,  Angela Abdollahi ,  Margaret Favata ,  Jonathan Rios-Doria ,  Hui Wang ,  Susan Wee ,  Pei Gan ,  Jeffrey C. Yang ,  Yong Li ,  Le Zhao ,  Chunhong He ,  Chunyin Marshall Law ,  Wenyu Zhu ,  Xiaozhao Wang ,  Wenqing Yao ,  Peter Niels Carlsen ,  Fenglei Zhang ,  Qinda Ye ,  Matthew S. McCammant ,  Rocco Policarpo ,  Artem Shvartsbart ,  Jeremy Roach ,  Gia Hoang ,  Bin Hu ,  Gencheng Li ,  Robert Susick ,  Padmaja Polam ,  Chao Qi ,  Alexander Sokolsky ,  Haolin Yin ,  Chang Min

IPC分类号： A61K31/4745 ,  A61P35/00 ,  A61P11/00 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/498 ,  A61K31/506 ,  A61K45/06

CPC分类号： A61K31/4745 ,  A61P35/00 ,  A61P11/00 ,  A61K31/5377 ,  A61K31/519 ,  A61K31/498 ,  A61K31/506 ,  A61K45/06

摘要： The present disclosure relates to methods of treating cancer by administering a compound, which is a Fibroblast Growth Factor Receptor (FGFR) inhibitor, in combination with a Kirsten rat sarcoma (KRAS) inhibitor.

公开(公告)号：US20230218611A1

公开(公告)日：2023-07-13

申请号：US17997203

申请日：2021-04-28

申请人： SENTISS PHARMA PRIVATE LIMITED

发明人： Manoj NAHAR ,  Shailendra PRASAD ,  Mallinath HARWALKAR ,  Kishor DEO ,  Deepak BAHRI

IPC分类号： A61K31/498 ,  A61K31/542 ,  A61K47/36 ,  A61K47/10 ,  A61K9/00 ,  A61P27/06

CPC分类号： A61K31/498 ,  A61K31/542 ,  A61K47/36 ,  A61K47/10 ,  A61K9/0048 ,  A61P27/06

摘要： An aqueous ophthalmic composition, comprising: a therapeutically effective amount of brimonidine or their salts thereof; a therapeutically effective amount of brinzolamide or their salts thereof; buffers at a concentration that is at least about 0.05% w/v to 5.0% w/v of the ophthalmic composition; a preservative and; pharmaceutically acceptable excipients, wherein the pH of said composition is less than 8.0.

公开(公告)号：US11684620B2

公开(公告)日：2023-06-27

申请号：US17125261

申请日：2020-12-17

申请人： ASTEX THERAPEUTICS LTD

发明人： Diego Fernando Domenico Broggini

IPC分类号： A61K31/498 ,  A61K47/26 ,  A61K47/18 ,  A61K9/20 ,  A61K9/48 ,  C09K15/20

CPC分类号： A61K31/498 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  A61K47/18 ,  A61K47/26 ,  C09K15/20

摘要： The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer.

公开(公告)号：US20230174562A1

公开(公告)日：2023-06-08

申请号：US17923831

申请日：2021-05-07

申请人： TONIX PHARMACEUTICALS, INC. ,  TONIX PHARMACEUTICALS HOLDING CORP.

发明人： Philip S. Schein ,  Darryl C. Rideout

IPC分类号： C07F9/165 ,  A61K45/06 ,  A61P39/00 ,  A61K31/661 ,  C07D243/08 ,  A61K31/551 ,  C07D241/04 ,  A61K31/495 ,  C07D243/10 ,  C07D245/02 ,  A61K31/395 ,  C07D245/04 ,  C07D487/04 ,  A61K31/4985 ,  C07C53/18 ,  C07D241/38 ,  A61K31/498 ,  C07F9/6571 ,  A61K31/675 ,  C07C323/25 ,  A61K31/145

CPC分类号： C07F9/1651 ,  A61K45/06 ,  A61P39/00 ,  A61K31/661 ,  C07D243/08 ,  A61K31/551 ,  C07D241/04 ,  A61K31/495 ,  C07D243/10 ,  C07D245/02 ,  A61K31/5545 ,  C07D245/04 ,  C07D487/04 ,  A61K31/4985 ,  C07C53/18 ,  C07D241/38 ,  A61K31/498 ,  C07F9/657118 ,  A61K31/675 ,  C07C323/25 ,  A61K31/145 ,  C07B2200/13

摘要： The present disclosure relates to prodrugs, double prodrugs, derivatives and analogues of 3-(methylamino)-2-((methy-lamino)methyl)propane-1-thiol. Their use as radio- and chemo-protectors is also described.

公开(公告)号：US20230119149A1

公开(公告)日：2023-04-20

申请号：US18083999

申请日：2022-12-19

申请人： JJG IP Holdings LLC

发明人： John F. Green ,  Peter A. Mendre

IPC分类号： B07C5/34 ,  A61K9/00 ,  A61K47/10 ,  A61K47/18 ,  A61K47/32 ,  A61K47/38 ,  B07C5/342 ,  B07C5/36 ,  A61K31/498 ,  C07C51/41 ,  C07C65/11 ,  C07D403/12

摘要： A system is provided for the identification and separation of heterogeneous material, the system comprising: a hyperspectral identification system for capturing spectra of material; a computer receiving and analyzing data from the hyperspectral identification system and selecting desired materials from the heterogeneous materials; and an ejection system, whereby the desired materials are ejected from the system.

公开(公告)号：US20230099018A1

公开(公告)日：2023-03-30

申请号：US17891869

申请日：2022-08-19

申请人： University of Massachusetts

发明人： Celia A. Schiffer ,  Akbar Ali ,  Ashley N. Matthew

IPC分类号： C07D241/20 ,  C07K5/083 ,  C07K5/103 ,  C07K5/107 ,  A61P31/14 ,  A61K31/498

摘要： The invention provides novel classes of HCV therapeutics that are orally available, safe and effective HCV NS3/4A protease inhibitors and are less susceptible to drug resistance than existing therapeutics. The invention also relates to pharmaceutical composition of these compounds and methods of preparation and use thereof.

公开(公告)号：US11590154B2

公开(公告)日：2023-02-28

申请号：US17364124

申请日：2021-06-30

申请人： RedHill Biopharma Ltd.

发明人： Reza Fathi ,  Gilead Raday ,  Patricia Anderson ,  Elliot Offman

IPC分类号： A61K31/7048 ,  A61K31/438 ,  A61P31/04 ,  A61K9/00 ,  A61K47/10 ,  A61K31/498

摘要： A fixed-dose combination drug product formulated for oral delivery comprises a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin. The fixed-dose combination drug product is sufficiently designed for use in treating pulmonary Mycobacterium avium Complex (MAC) disease in a subject in need thereof. A method for treating MAC disease in a human having MAC lung infection comprising orally administering, twice daily, about 475 mg of clarithromycin, about 40 mg of clofazimine and about 120 mg of rifabutin. A kit for treating pulmonary MAC disease in an individual having MAC lung infection comprises a supply of fixed-dose combination drug products, wherein each of the fixed-dose combination drug products comprise a fixed 158.3 mg dose of clarithromycin, a fixed 13.3 mg dose of clofazimine and a fixed 40.0 mg dose of rifabutin; and instructions for use.